Back to User profile » Dr Kamal Hamed

Papers published by Dr Kamal Hamed:

Erratum

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials [Erratum]

Hamed K, Wiktorowicz T, Assadi Gehr M

Infection and Drug Resistance 2020, 13:3461-3462

Published Date: 7 October 2020

Original Research

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials

Hamed K, Wiktorowicz T, Assadi Gehr M

Infection and Drug Resistance 2020, 13:3209-3215

Published Date: 16 September 2020

Original Research

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015

Santerre Henriksen A, Smart JI, Hamed K

Infection and Drug Resistance 2018, 11:1309-1320

Published Date: 28 August 2018

Original Research

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data

Hamed K, Conti V, Tian H, Loefroth E

Patient Preference and Adherence 2017, 11:831-838

Published Date: 27 April 2017

Review

Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections

Gonzalez-Ruiz A, Seaton RA, Hamed K

Infection and Drug Resistance 2016, 9:47-58

Published Date: 15 April 2016